Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon Inc (NQ: ANNX )

4.580 +0.140 (+3.15%)
Streaming Delayed Price Updated: 1:39 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annexon Inc

< Previous 1 2 Next >
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
From Annexon Biosciences
Via GlobeNewswire
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET 
From Annexon Biosciences
Via GlobeNewswire
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.